Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

Margaret V. Ragni, MD MPH, Pencho Georgiev, MD, Michael Desmond Creagh, Toshko Jelev Lissitchkov, MD, Steve K. Austin, BMedSci, MBBS, Charles Richard Morris Hay, MDFRCP, FRCPath, Inga Hegemann, MD, Syed Rashid Saeed Kazmi, MBBS, Pratima Chowdary, MD, Savita Rangarajan, MBBS, MD, Meredith C. Foster, ScD, Qifeng Yu, PhD, Craig Benson, MD MS, Kate Madigan, MD, Huy Van Nguyen, PharmD, Shariq Ali, PhD, Ketaki Kadam, MS, Pallavi Jain, PharmD, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH

Blood (2018) 132 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2018-99-112998

Published: 2018

Journal Articles

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

Andreas Tiede, MD, Georg Goldmann, Predrag S Miljić, Lars Korsholm, Irina Matytsina, Paula Persson, Toshko Jelev Lissitchkov, MD

Blood (2018) 132 (Supplement 1): 2491.

https://doi.org/10.1182/blood-2018-99-111269

Published: 2018

Journal Articles

Pharmacodynamics, Pharmacokinetics and Safety of Bay 1093884, an Antibody Directed Against Human TFPI, in Patients with Factor VIII or IX Deficiency (With and Without Inhibitors): A Phase 1 Study

Pratima Chowdary, MD, Toshko Jelev Lissitchkov, MD, Stefan Willmann, Dr, Stephan Schwers, PhD, Lisa A. Michaels, Anita Shah

Blood (2018) 132 (Supplement 1): 1176.

https://doi.org/10.1182/blood-2018-99-114683

Published: 2018

Journal Articles

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Claude Negrier, MD, Margaret V. Ragni, MD MPH, Pencho Georgiev, MD, Toshko Jelev Lissitchkov, MD PhD, Huy Van Nguyen, PharmD, Kate Madigan, K John Pasi

Blood (2017) 130 (Supplement 1): 2366.

https://doi.org/10.1182/blood.V130.Suppl_1.2366.2366

Published: 2017

Journal Articles

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Bruce A. Schwartz, PhD, Cecil Ross, MD, Bella Madan, MD, Toshko Jelev Lissitchkov, MD, Mehran Karimi, MD, Sigurd Knaub, Flora Peyvandi, MD PhD

Blood (2016) 128 (22): 1404.

https://doi.org/10.1182/blood.V128.22.1404.1404

Published: 2016

Journal Articles

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Nirjhar Chatterjee, MD

Blood (2016) 128 (22): 4978.

https://doi.org/10.1182/blood.V128.22.4978.4978

Published: 2016

Journal Articles

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Vasily Mamonov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2585.

https://doi.org/10.1182/blood.V128.22.2585.2585

Published: 2016

NARROW

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

Pharmacodynamics, Pharmacokinetics and Safety of Bay 1093884, an Antibody Directed Against Human TFPI, in Patients with Factor VIII or IX Deficiency (With and Without Inhibitors): A Phase 1 Study

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

Pharmacodynamics, Pharmacokinetics and Safety of Bay 1093884, an Antibody Directed Against Human TFPI, in Patients with Factor VIII or IX Deficiency (With and Without Inhibitors): A Phase 1 Study

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only